Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s DiseaseCAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first person dosed in a Phase 2 clinical trial in isolated dystonia with VIM0423, a potential first-in-class oral therapy, and the extension of its Series A financing to $100M. The round included participation from new investor Frazier Life Sciences (FLS) and existing investors Atlas Venture, Access Industries, and Canaan Partners. Joe Cabral, Partner at FLS, will join Vima’s Board of Directors. The financing will enable the company to complete two Phase 2 trials with VIM0423 for isolated dystonia and Parkinson’s disease. The company expects to initiate a Phase 2 trial in Parkinson’s disease in mid-2026, with topline data from both trials anticipated in the first half of 2027.
